New Phase 3 trial: A Study to Confirm Efficacy of a Single Dose of Baloxavir Marboxil in the Post-exposure Prophylaxis (PEP) of Influenza Virus Infection in Chinese Participants — Hoffmann-La Roche
Why now
Thesis: Roche tests baloxavir for influenza post-exposure prophylaxis
Catalyst to watch: Trial enrollment or interim data
Main risk: Years from commercial read-through
Why it matters
Not-yet-recruiting trial in China; years from any commercial read-through.
Details
Sponsor: Hoffmann-La Roche; Status: Not Yet Recruiting; Conditions: Influenza, Human, Respiratory Tract Infections, Post-exposure Prophylaxis; Interventions: Baloxavir marboxil, Placebo; Enrollment: 325 (estimated); First posted: 2026-09-18; NCT: NCT07827599
Sources
- clinicaltrials · 2026-09-18 12:00 UTC